NewAmsterdam Pharma (NAMS) Cash & Equivalents (2021 - 2026)
NewAmsterdam Pharma's Cash & Equivalents came in at $424.15 million for Q2 2026, down 24.8% from $563.86 million a year earlier and down 7.3% from the prior quarter.
Powered by 
Analysis
NewAmsterdam Pharma (NAMS) Cash & Equivalents (2021 - 2026) Analysis & Trends
At the end of FY2025, NewAmsterdam Pharma's Cash & Equivalents was $490 million, down 36.5% from FY2024.
- Cash & Equivalents carries a five-year compound annual growth rate of 122.6% (FY2020 to FY2025).
- Going back by year, Cash & Equivalents was $771.74 million in FY2024 (+126.7%), $340.45 million in FY2023 (-27.2%), $467.73 million in FY2022 (+677.8%) and $60.13 million in FY2021 (+569.9%).
- The Q2 2026 figure represents the lowest quarterly Cash & Equivalents since Q3 2024.
- Year-over-year, Cash & Equivalents has declined for three consecutive quarters, with growth averaging 19.4% over the last eight quarters.
- The fastest year-over-year change in Cash & Equivalents over five years came in Q4 2022 (growth of 636.6%), and the weakest in Q1 2026 (a decline of 38.9%).
- Business Quant data shows NAMS's Cash & Equivalents at $457.61 million (Q1 2026), $490 million (Q4 2025) and $538.41 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 976.00 Mn |
| 10 | NewAmsterdam Pharma | 2.73 Bn | 2.73 Bn | - | 424.15 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 424.15 Mn |
| Mar 31, 2026 | 457.61 Mn |
| Dec 31, 2025 | 490.00 Mn |
| Sep 30, 2025 | 538.41 Mn |
| Jun 30, 2025 | 563.86 Mn |
| Mar 31, 2025 | 748.42 Mn |
| Dec 31, 2024 | 771.74 Mn |
| Sep 30, 2024 | 422.73 Mn |
| Jun 30, 2024 | 430.71 Mn |
| Mar 31, 2024 | 481.15 Mn |
| Dec 31, 2023 | 340.45 Mn |
| Sep 30, 2023 | 368.31 Mn |
| Jun 30, 2023 | 416.71 Mn |
| Mar 31, 2023 | 441.31 Mn |
| Dec 31, 2022 | 447.40 Mn |
| Dec 31, 2021 | 60.74 Mn |
API Access
NewAmsterdam Pharma Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=NAMS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "NAMS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=NAMS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();